Source: GlobalNewswire

Press Release: Otonomy : Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus

SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the completion of patient enrollment in the Phase 2 clinical trial of OTO-313 in tinnitus.

Read full article »
Otonomy's Competitors | Otonomy's News | Otonomy's Financials
Stay up-to-date with the latest news on Otonomy
Annual Revenue
$100K-5.0M
Employees
25-100
David A Weber's photo - President & CEO of Otonomy

President & CEO

David A Weber

CEO Approval Rating

88/100

Read more
Stay up-to-date with the latest news on Otonomy